DIA
Drug Information Association Logo

Advanced Search

Search Poster Presentations

Search Poster Presentation 

Poster Number Poster Title Poster Type Date/Time Poster Presenter
P01 The post-WHI era: after 10 years, the debate on HRT’s risk/benefit balance is still ongoing. Professional Tue, Mar 27 9:00AM Simonetta Alvino
P02 Pharmacovigilance requirements for a documentation system and quality management practices Professional Tue, Mar 27 9:00AM Solveig Blomvik
P03 Variation (MRP) of marketing authorisations: Experience with the new variation regulation Professional Tue, Mar 27 9:00AM Susanne Brendler-Schwaab
P04 Independent clinical research funding: successes, impact and issues of the Italian Medicine Agency (AIFA) initiative Professional Tue, Mar 27 9:00AM Carlo Tomino
P05 A Comparison of Regulatory Evidence Techniques used by Pharma and Regulators re: Investigator Misconduct in Clinical Trials Professional Tue, Mar 27 9:00AM Sherri A. Hubby
P06 Impact of drug information service on adverse drug reaction inquiries by patients Professional Tue, Mar 27 9:00AM Pongsak Kooprasertying
P07 The safer vaccines & immunobiological Products means healthy people Professional Tue, Mar 27 9:00AM Merita Kucuku
P08 Stimulation of Drug Rediscovery -Towards a marketing authorization for new applications of existing drugs Professional Tue, Mar 27 9:00AM Joris Langedijk
P09 Data Management, Compliance and GxP Cloud Computing Professional Tue, Mar 27 9:00AM Niels Leander
P10 Regulatory Requirements for Clinical Trials Involving Deliberate Release of a GMO: A Global Perspective Professional Tue, Mar 27 9:00AM John Watkins
P11 An audit of Serious Adverse Events (SAE) reported by investigators involved in a phase III multicentre, multinational oncology Professional Tue, Mar 27 9:00AM Nicola McElroy
P12 Integrating Virtual IT Systems that Streamline Management of Clinical Trial Samples and Associated Clinical Data Professional Tue, Mar 27 9:00AM Malcom McIntyre
P13 Pharma Quality Agreements Professional Tue, Mar 27 9:00AM Gloria Miller
P14 ‘Risk-based protection of trial participants in un-notified clinical trials’ -Compensation to participants in Japan- Professional Tue, Mar 27 9:00AM Toshinori Murayama
P15 Disease management of cancer–associated anaemia and potential savings from the use of Biosimilar ESAs in Greece Professional Tue, Mar 27 9:00AM Eleftheria Nikolaidi
P16 MOBILE PHONE USE IN PATIENT REPORTED OUTCOMES – A LITERATURE SEARCH Professional Tue, Mar 27 9:00AM Hannah O'Gorman
P17 PhRMA-Japan survey on the Global Studies Professional Tue, Mar 27 9:00AM Yoshihiko Ono
P18 Quality management principles implementation – impact on Serbian medicines regulatory authority performance improvement Professional Tue, Mar 27 9:00AM Gordana Pejovic
P19 ENHANCEMENT OF REGULATORY PROCEDURES ON MEDICINAL PRODUCTS IN MEDICINES AND MEDICAL DEVICES AGENCY OF SERBIA – PATIENTS INFOR Professional Tue, Mar 27 9:00AM Vesela Radonjic
P20 Assessment of the Nonclinical Safety of Homeopathic Preparations Containing Protoanemonin by Applying QSAR Methodology Professional Tue, Mar 27 9:00AM Hans Heinrich Rensland
P21 Time for reinterpretation of a trusted guideline? Professional Tue, Mar 27 9:00AM Thomas Martin Schindler
P22 An Analysis of Serbian Pharmacovigilance System Professional Tue, Mar 27 9:00AM Tatjana B Sipetic
P23 The INTEGRITY Study: Measuring the Impact of Sample Preparation Techniques and Storage Temperatures on the Integrity DNA Professional Tue, Mar 27 9:00AM Piet Smet
P24 FDA Reporting Update for Clinical Trials – Final Rule effective as of 28 March 2011 Professional Tue, Mar 27 9:00AM Anika Staack
P25 CONSIDERATIONS FOR ADOPTING CDISC STANDARDS Professional Tue, Mar 27 9:00AM Hanming H Tu
P26 The Global Supply Chain: Challenges From the Industry and Regulator Perspective Professional Tue, Mar 27 9:00AM Eilt Van der Star
SP01 Clinical development methodologies for pharmacogenomic biomarkers: the first European regulatory step Student Tue, Mar 27 10:00AM Aurelia Arry
SP02 A critical review of FDA database to find redundancies in pediatric RCTs Student Tue, Mar 27 10:00AM Marion Bichet
SP03 Correlation between drug licensing and economic output: evidence from 151 drugs marketed in USA? Student Tue, Mar 27 10:00AM Chen Cao
SP04 Systemic Lupus Erythematosus – Analysis of plasma cell survival in autoimmune inflamed tissues Student Tue, Mar 27 10:00AM João Conniot
SP05 First step toward a new Paradigm for Rare Diseases: Designing a discursive model Student Tue, Mar 27 10:00AM Anne-Sophie Paradis
SP06 Materiovigilance in some hospitals from Cluj-Napoca, Romania Student Tue, Mar 27 10:00AM Elena Fasniuc
SP07 Analysis of drug withdrawn flood: empirical research on total withdrawn drugs from 1991 to 2010 Student Tue, Mar 27 10:00AM Liu Feng
SP08 EPSA Annual Questionnaire 2010-2011: Pharmacovigilance - keeping our eyes open and our medicines safe Student Tue, Mar 27 10:00AM Charlene Galea
SP09 Do statins prevent sudden cardiac death in all patients ? Student Tue, Mar 27 10:00AM Samira Hadj Sadok
SP10 Assessing the needs and preferences of the pharmacy students related to soft skills education Student Tue, Mar 27 10:00AM Inkatuuli Heikkinen
SP11 Regulatory Aspects of Modeling and Simulation in Pediatric Drug Development Student Tue, Mar 27 10:00AM Ellina Kovalenko
SP12 Safety data in clinical trials and personal data protection Student Tue, Mar 27 10:00AM Juliane Preuss
SP13 Evaluation of Prescribing Trends and Rationality of Use of Oral Proteolytic Enzymes Student Tue, Mar 27 10:00AM Saumil Ashvin Shah
SP14 The Assessment of Public's Knowledge of Antibiotic Use in Lithuania Student Tue, Mar 27 10:00AM Egle Svitojute
SP15 Antinociceptive Effect of Levetiracetam in Orofacial Formalin Test in Rats Student Tue, Mar 27 10:00AM Branko Vukosavljevic
© 2015 DIA